In vitro and in vivo studies have demonstrated that co-occurring mutations of STK11 and KEAP1 in KRAS-mutant NSCLC promote tumor growth and confer enhanced resistance to radiotherapy (116). Here, KRAS is linked to non-small cell lung carcinoma.